Cantargia Reports Updated Interim Results of Nadunolimab in P-I/IIa (CANFOUR) Trial for the Treatment of Pancreatic Cancer
Shots:
- The P-I/IIa (CANFOUR) trial evaluates nadunolimab + CT (gemcitabine & nab-paclitaxel) in patients with PDAC. The results are expected in H1’22
- In interim results, the therapy showed median survival (12.7mos. vs 8.5mos.) over historical data in patients with gemcitabine & nab-paclitaxel, 1yr. survival rate (55% vs 35%), m-iPFS (7.2mos.) & 6mos. iPFS (56%), 2 patients continued on treatment & 12 patients were still alive, safety & response rates are similar to previous results
- The results showed m-PFS (5.5mos.) with a 6mos. PFS of 44% in patients with CT. The therapy is being evaluated in multiple trials while the company is planning for a randomized & pivotal trial for pancreatic cancer
Ref: Cision | Image: LinkedIn
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com